B. Riley lowered the firm’s price target on Biote (BTMD) to $9 from $10 and keeps a Buy rating on the shares. Biote’s Q4 revenue and AEBITDA were below estimates, while gross margin exceeded expectations, the analyst tells investors in a research note. The company has enough capacity through the vertical integration of its 503B manufacturing facility to meet demands for pellets as it becomes licensed in additional states, the firm says.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTMD: